Mark Domko stays in good shape, doesn’t smoke, doesn’t drink, and gets regular checkups with his doctor. That’s why his prostate cancer diagnosis came as such a shock in 2014. A biopsy soon confirmed it was a fast-growing cancer and Mark was scheduled for a radical prostatectomy and hormone therapy.
Accessible molecular testing contributing to better outcomes for Manitobans
Molecular testing has become more accessible for Manitobans living with cancer after physicians saw its importance in providing patients with the best possible treatment, based on their genetic profile. CCMB researchers conducted a study to test the effectiveness of a new class of medications, PARP inhibitors, in treating metastatic castrate-resistant prostate cancer patients with alterations within BRCA and ATM genes. …
- Page 2 of 2
- 1
- 2